Literature DB >> 17875987

Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells.

Hiroshi Tazawa1, Naoto Tsuchiya, Masashi Izumiya, Hitoshi Nakagama.   

Abstract

Accumulating evidence suggests a role for microRNAs in human carcinogenesis as novel types of tumor suppressors or oncogenes. However, their precise biological role remains largely elusive. In the present study, we aimed to identify microRNA species involved in the regulation of cell proliferation. Using quantitative RT-PCR analysis, we demonstrated that miR-34a was highly up-regulated in a human colon cancer cell line, HCT 116, treated with a DNA-damaging agent, adriamycin. Transient introduction of miR-34a into two human colon cancer cell lines, HCT 116 and RKO, caused complete suppression of cell proliferation and induced senescence-like phenotypes. Moreover, miR-34a also suppressed in vivo growth of HCT 116 and RKO cells in tumors in mice when complexed and administered with atelocollagen for drug delivery. Gene-expression microarray and immunoblot analyses revealed down-regulation of the E2F pathway by miR-34a introduction. Up-regulation of the p53 pathway was also observed. Furthermore, 9 of 25 human colon cancers (36%) showed decreased expression of miR-34a compared with counterpart normal tissues. Our results provide evidence that miR-34a functions as a potent suppressor of cell proliferation through modulation of the E2F signaling pathway. Abrogation of miR-34a function could contribute to aberrant cell proliferation, leading to colon cancer development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17875987      PMCID: PMC2000550          DOI: 10.1073/pnas.0707351104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

Review 1.  MicroRNA signatures in human cancers.

Authors:  George A Calin; Carlo M Croce
Journal:  Nat Rev Cancer       Date:  2006-11       Impact factor: 60.716

2.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.

Authors:  George Adrian Calin; Manuela Ferracin; Amelia Cimmino; Gianpiero Di Leva; Masayoshi Shimizu; Sylwia E Wojcik; Marilena V Iorio; Rosa Visone; Nurettin Ilfer Sever; Muller Fabbri; Rodolfo Iuliano; Tiziana Palumbo; Flavia Pichiorri; Claudia Roldo; Ramiro Garzon; Cinzia Sevignani; Laura Rassenti; Hansjuerg Alder; Stefano Volinia; Chang-gong Liu; Thomas J Kipps; Massimo Negrini; Carlo M Croce
Journal:  N Engl J Med       Date:  2005-10-27       Impact factor: 91.245

Review 3.  Involvement of E2F transcription factor family in cancer.

Authors:  P K Tsantoulis; V G Gorgoulis
Journal:  Eur J Cancer       Date:  2005-10-05       Impact factor: 9.162

4.  Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo.

Authors:  Fumitaka Takeshita; Yoshiko Minakuchi; Shunji Nagahara; Kimi Honma; Hideo Sasaki; Kotaro Hirai; Takumi Teratani; Nachi Namatame; Yusuke Yamamoto; Koji Hanai; Takashi Kato; Akihiko Sano; Takahiro Ochiya
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-09       Impact factor: 11.205

5.  The HBP1 transcriptional repressor participates in RAS-induced premature senescence.

Authors:  Xiaowei Zhang; Jiyoung Kim; Robin Ruthazer; Michael A McDevitt; David E Wazer; K Eric Paulson; Amy S Yee
Journal:  Mol Cell Biol       Date:  2006-09-11       Impact factor: 4.272

6.  MicroRNA responses to cellular stress.

Authors:  Carmen J Marsit; Karen Eddy; Karl T Kelsey
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

7.  Control of the p53-p21CIP1 Axis by E2f1, E2f2, and E2f3 is essential for G1/S progression and cellular transformation.

Authors:  Nidhi Sharma; Cynthia Timmers; Prashant Trikha; Harold I Saavedra; Amanda Obery; Gustavo Leone
Journal:  J Biol Chem       Date:  2006-09-27       Impact factor: 5.157

Review 8.  Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?

Authors:  Stephen B Baylin; Joyce E Ohm
Journal:  Nat Rev Cancer       Date:  2006-02       Impact factor: 60.716

9.  SND1, a component of RNA-induced silencing complex, is up-regulated in human colon cancers and implicated in early stage colon carcinogenesis.

Authors:  Naoto Tsuchiya; Masako Ochiai; Katsuhiko Nakashima; Tsuneyuki Ubagai; Takashi Sugimura; Hitoshi Nakagama
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

10.  A microRNA expression signature of human solid tumors defines cancer gene targets.

Authors:  Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

View more
  386 in total

1.  Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets.

Authors:  Massimiliano Agostini; Paola Tucci; Richard Killick; Eleonora Candi; Berna S Sayan; Pia Rivetti di Val Cervo; Pierluigi Nicotera; Frank McKeon; Richard A Knight; Tak W Mak; Gerry Melino
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

2.  Behavioral plasticity in honey bees is associated with differences in brain microRNA transcriptome.

Authors:  J K Greenberg; J Xia; X Zhou; S R Thatcher; X Gu; S A Ament; T C Newman; P J Green; W Zhang; G E Robinson; Y Ben-Shahar
Journal:  Genes Brain Behav       Date:  2012-04-06       Impact factor: 3.449

3.  p53-Dependent induction of PVT1 and miR-1204.

Authors:  Anthony M Barsotti; Rachel Beckerman; Oleg Laptenko; Konrad Huppi; Natasha J Caplen; Carol Prives
Journal:  J Biol Chem       Date:  2011-11-22       Impact factor: 5.157

4.  Multiple E2F-induced microRNAs prevent replicative stress in response to mitogenic signaling.

Authors:  María J Bueno; Marta Gómez de Cedrón; Usua Laresgoiti; José Fernández-Piqueras; Ana M Zubiaga; Marcos Malumbres
Journal:  Mol Cell Biol       Date:  2010-04-19       Impact factor: 4.272

5.  miR-29 and miR-30 regulate B-Myb expression during cellular senescence.

Authors:  Ivan Martinez; Demian Cazalla; Laura L Almstead; Joan A Steitz; Daniel DiMaio
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

Review 6.  Regulation of senescence by microRNA biogenesis factors.

Authors:  Kotb Abdelmohsen; Subramanya Srikantan; Min-Ju Kang; Myriam Gorospe
Journal:  Ageing Res Rev       Date:  2012-01-28       Impact factor: 10.895

7.  Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.

Authors:  Maria T Di Martino; Emanuela Leone; Nicola Amodio; Umberto Foresta; Marta Lionetti; Maria R Pitari; Maria E Gallo Cantafio; Annamaria Gullà; Francesco Conforti; Eugenio Morelli; Vera Tomaino; Marco Rossi; Massimo Negrini; Manlio Ferrarini; Michele Caraglia; Masood A Shammas; Nikhil C Munshi; Kenneth C Anderson; Antonino Neri; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Clin Cancer Res       Date:  2012-10-03       Impact factor: 12.531

8.  p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest.

Authors:  Christian J Braun; Xin Zhang; Irina Savelyeva; Sonja Wolff; Ute M Moll; Troels Schepeler; Torben F Ørntoft; Claus L Andersen; Matthias Dobbelstein
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

9.  MiR-34a suppresses amphiregulin and tumor metastatic potential of head and neck squamous cell carcinoma (HNSCC).

Authors:  Jiali Zhang; Yu Wang; Xinming Chen; Yi Zhou; Fangyan Jiang; Jirong Chen; Li Wang; Wen-Feng Zhang
Journal:  Oncotarget       Date:  2015-04-10

10.  MiR-34a promotes Fas-mediated cartilage endplate chondrocyte apoptosis by targeting Bcl-2.

Authors:  Huajiang Chen; Jianxi Wang; Bo Hu; Xiaodong Wu; Yu Chen; Renhu Li; Wen Yuan
Journal:  Mol Cell Biochem       Date:  2015-04-25       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.